The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
Open Access
- 13 December 2011
- journal article
- research article
- Published by Hindawi Limited in Obstetrics and Gynecology International
- Vol. 2012, 1-6
- https://doi.org/10.1155/2012/658310
Abstract
Angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are known to cause fetal renal damage in pregnancy. Due to conflicting reports in the literature, their safety after first trimester exposure has been debated. Our aim was to determine whether the use of ACE inhibitors or ARBs in the first trimester of pregnancy is associated with an increased risk for major malformations or other adverse outcomes. All subjects were prospectively enrolled from among women contacting a teratogen information service. At initial contact, details of maternal medical history and exposures were collected and follow-up interviews were conducted to ascertain pregnancy outcomes. Two comparator groups, women with hypertension treated with other antihypertensives, and healthy controls were also recruited. Baseline maternal characteristics were not different among the three groups. There were no differences in rates of major malformations. Both the ACE-ARBs and disease-matched groups exhibited significantly lower birth weight and gestational ages than the healthy controls (for both variables). There was a significantly higher rate of miscarriage noted in the ACE/ARB group (). These results suggest that ACE inhibitors/ARBs are not major human teratogens; however, they may be associated with an increased risk for miscarriage.
Keywords
This publication has 35 references indexed in Scilit:
- Use of ACE inhibitors and ARBs in hypertensive women of childbearing ageJournal of Clinical Pharmacy & Therapeutics, 2008
- Outpatient use of cardiovascular drugs during pregnancyPharmacoepidemiology and Drug Safety, 2008
- Non-lethal fetal toxicity of the angiotensin receptor blocker candesartanPediatric Nephrology, 2006
- Fetal toxicity of valsartan and possible reversible adverse side effectsBirth Defects Research Part A: Clinical and Molecular Teratology, 2004
- Defective embryogenesis with angiotensin II receptor antagonists in pregnancyBJOG: An International Journal of Obstetrics and Gynaecology, 2003
- The safety of valsartan: results of a postmarketing surveillance study on 12 881 patients in EnglandJournal of Human Hypertension, 2002
- Management of mild chronic hypertension during pregnancy: a review*1Obstetrics & Gynecology, 2000
- Perinatal morbidity in chronic hypertensionBJOG: An International Journal of Obstetrics and Gynaecology, 1996
- Angiotensin‐converting enzyme inhibitors during pregnancy: a survey of 22 patients given captopril and nine given enalaprilBJOG: An International Journal of Obstetrics and Gynaecology, 1988
- Effect of Captopril on Uterine Blood Flow and Prostaglandin E Synthesis in the Pregnant RabbitJCI Insight, 1983